It is well known that the HR pathway plays an important role in the development of ovarian cancer, and a defect in its function would potentially lead to a greater susceptible of tumor cells to drugs that are damaging to the cellular genome, including PARP inhibitors.14 Here, PARP1 is linked to neoplasm.